跳至主要内容
临床试验/CTRI/2023/09/057488
CTRI/2023/09/057488招募中不适用

Role of Individualized Homoeopathic Medicine in 50 Millesimal Potencies in the Treatment of Acne Vulgaris: A Single Arm Pre-test Post-test Interventional Trial

National Institute of Homoeopathy1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2023年9月15日最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
50
试验地点
1
主要终点
Numerical pain rating scale (0-10)

研究概览

简要总结

Acne is a chronic inflammatory disease of the pilosebaceous unit resulting from androgen-induced increased sebum production, altered keratinisation, inflammation, and bacterial colonisation of hair follicles on the face, neck, chest, and back by Propioni bacterium acnes. Acne is estimated to affect 9.4% of the global population, making it the 8th most prevalent disease worldwide. From a homoeopathic perspective, skin diseases are the manifestations of an internal or constitutional disorder. Thus, the treatment of skin diseases is strictly based on constitutional criteria. Homoeopathy has produced few evidences in the treatment of Acne vulgaris. But the condition has not been researched yet using 50 millesimal potencies. Fifty millesimal potencies already having some evidences in treating acute or chronic diseases in its favour. Therefore, we shall undertake this study to explore the usefulness of individualized homoeopathic medicine in 50 millesimal potencies in the management of Acne vulgaris. In this study the homoeopathic medicines are administered orally, which are already known and safe for human use. all the patients will be prescribed individualized homoeopathic medicines in 50 millesimal potencies. Dosese and repetition will be as per homoeopathic principles. Outcomes will be Global Acne Grading System (GAGS) score, Dermatology Life Quality of Index (DLQI) score, measured at baseline and 3 months of treatment. The possible causal attribution will be evaluated by using Modified Naranjo Criteria for Homeopathy (MONARCH) Score, measured at the end of treatment in all cases (after 3 months of treatment). 

Duration of therapy: 3 months.

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Not Applicable

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)

入选标准

  • 65 years. ii.Gender: Both Male and Female. iii.Diagnosed cases of Anal Fissure iv.Patients using topical agents for fissure will be included after a washout period of two weeks, subject to persistence of symptoms and signs of fissures v.Patient voluntarily giving written informed consent for the study.

排除标准

  • i.Severe co-morbidities or any other uncontrolled systemic diseases, life-threatening illness etc.
  • affecting Quality of Life.
  • ii.Pregnant or breast-feeding women.
  • iii.Substance abuse and/ or dependence.
  • iv.Psychologically unstable patients.
  • v.Previous history of surgical interventions for anal fissure.
  • vi.Diagnosed or any suspected cases of rectal malignancies vii.Under-going homoeopathic treatment for any chronic diseases for last 3 months.
  • viii.Patients who are unable to read the patient information sheet and written consent form.
  • ix.Patient unwilling to take part in the study and not giving written consent for this study.

结局指标

主要结局

Numerical pain rating scale (0-10)

时间窗: Baseline and after 3 months.

次要结局

  • To evaluate the changes in scoring of HEMO-FISS scale
  • Modified Naranjo Criteria for Homoeopathy (MONARCH)(After 3 months of treatment.)

研究者

申办方类型
Government medical college

研究点 (1)

Loading locations...

相似试验